DK1303269T3 - 3-substituerede oxindolderivater og deres anvendelse som KCNQ-kaliumkanalmodulatorer - Google Patents

3-substituerede oxindolderivater og deres anvendelse som KCNQ-kaliumkanalmodulatorer

Info

Publication number
DK1303269T3
DK1303269T3 DK01940246T DK01940246T DK1303269T3 DK 1303269 T3 DK1303269 T3 DK 1303269T3 DK 01940246 T DK01940246 T DK 01940246T DK 01940246 T DK01940246 T DK 01940246T DK 1303269 T3 DK1303269 T3 DK 1303269T3
Authority
DK
Denmark
Prior art keywords
potassium channel
channel modulators
oxindole derivatives
kcnq potassium
substituted oxindole
Prior art date
Application number
DK01940246T
Other languages
Danish (da)
English (en)
Inventor
Rikke L Schroeder
Dorte Stroebaek
Soeren Peter Olesen
Bo Skaaning Jensen
Original Assignee
Neurosearch As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch As filed Critical Neurosearch As
Application granted granted Critical
Publication of DK1303269T3 publication Critical patent/DK1303269T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
DK01940246T 2000-06-29 2001-06-14 3-substituerede oxindolderivater og deres anvendelse som KCNQ-kaliumkanalmodulatorer DK1303269T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200001022 2000-06-29
DKPA200100394 2001-03-08
PCT/DK2001/000412 WO2002000217A1 (en) 2000-06-29 2001-06-14 Use of 3-substituted oxindole derivatives as kcnq potassium channel modulators

Publications (1)

Publication Number Publication Date
DK1303269T3 true DK1303269T3 (da) 2006-03-20

Family

ID=26068847

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01940246T DK1303269T3 (da) 2000-06-29 2001-06-14 3-substituerede oxindolderivater og deres anvendelse som KCNQ-kaliumkanalmodulatorer

Country Status (12)

Country Link
US (1) US20030181507A1 (de)
EP (2) EP1634594A1 (de)
JP (1) JP2004501192A (de)
CN (1) CN1222288C (de)
AT (1) ATE311879T1 (de)
AU (2) AU7388701A (de)
CA (1) CA2412208C (de)
DE (1) DE60115656T2 (de)
DK (1) DK1303269T3 (de)
MX (1) MXPA03000032A (de)
NZ (1) NZ522794A (de)
WO (1) WO2002000217A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002072088A2 (en) * 2001-02-20 2002-09-19 Bristol-Myers Squibb Company Modulators of kcnq potassium channels and use thereof in treating migraine and mechanistically related diseases
AU2002338333A1 (en) * 2001-04-04 2002-10-21 Wyeth Methods for treating hyperactive gastric motility
WO2005035498A1 (ja) * 2003-10-08 2005-04-21 Dainippon Sumitomo Pharma Co., Ltd. 含窒素二環性化合物の摂食調節剤としての用途
EP1688141A1 (de) 2005-01-31 2006-08-09 elbion AG Verwendung von Flupirtine zur Behandlung der hyperaktiven Blase und damit zusammenhängender Erkrankungen und zur Behandlung des Reizdarmsyndroms
UA92340C2 (en) * 2005-03-03 2010-10-25 Х. Луннбек А/С Substituted pyridine derivatives
WO2007009462A2 (en) * 2005-07-15 2007-01-25 Region Hovedstaden V/Glostrup Hospital Treatment of migraine and headaches
FR2941947B1 (fr) * 2009-02-12 2011-03-25 Sanofi Aventis Derives de 3-benzofuranyl-indol-2-one subtitues en 3, leur preparation et leur application en therapeutique
FR2941946B1 (fr) * 2009-02-12 2011-03-25 Sanofi Aventis Derives de 3-benzofuranyl-indol-2-one-3-acetamidopiperazines substitues, leur preparation et leur application en therapeutique
WO2010105189A1 (en) * 2009-03-12 2010-09-16 The Johns Hopkins University Method for identifying compounds that attenuate the function or reduce abundance of a voltage-gated potassium channel and are associated with maintenance of cognitive function in old age
AU2010256541B2 (en) * 2009-06-03 2016-03-10 Marquette University Modulation of KCNQ potassium channel activity for treatment of psychiatric disorders and the symptoms thereof
KR101820645B1 (ko) * 2010-10-20 2018-01-22 그뤼넨탈 게엠베하 Ｋｃｎｑ２／３ 조절제로서의 치환된 ６­아미노­니코틴아미드
EP3160957B1 (de) * 2014-06-26 2018-06-06 F. Hoffmann-La Roche AG Indolin-2-on oder pyrrolo-pyridin-2-on-derivate
GB201502412D0 (en) * 2015-02-13 2015-04-01 Canbex Therapeutics Ltd Therapeutic use
MA43159B1 (fr) 2015-11-06 2020-08-31 Hoffmann La Roche Dérivés d'indoline-2-one
JP6857653B2 (ja) 2015-11-06 2021-04-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃｎｓ及び関連障害の治療において使用するためのインドリン−２−オン誘導体
EP3371170B1 (de) 2015-11-06 2019-07-31 H. Hoffnabb-La Roche Ag Indolin-2-on-derivate zur behandlung von erkrankungen des zentralen nervensystems (zns)
CN108137561B (zh) 2015-11-06 2021-03-26 豪夫迈·罗氏有限公司 二氢吲哚-2-酮衍生物
AU2017275657B2 (en) 2016-06-02 2021-08-19 Novartis Ag Potassium channel modulators
US9975886B1 (en) 2017-01-23 2018-05-22 Cadent Therapeutics, Inc. Potassium channel modulators
US20180207138A1 (en) * 2017-01-23 2018-07-26 Cadent Therapeutics, Inc. Methods for the treatment of tremors by positive modulation of sk channels
US10265300B2 (en) * 2017-02-24 2019-04-23 Ovid Therapeutics Inc. Methods of treating seizure disorders
EP3912625A1 (de) 2020-05-20 2021-11-24 Kaerus Bioscience Limited Neuartige maxi-k-kaliumkanal-öffner zur behandlung von mit fragilem x assoziierten erkrankungen

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736578A (en) * 1995-06-06 1998-04-07 Bristol-Myers Squibb Company Ethylamido fluorenes and improved method of making same
US5565483A (en) * 1995-06-07 1996-10-15 Bristol-Myers Squibb Company 3-substituted oxindole derivatives as potassium channel modulators
TW457233B (en) * 1996-10-11 2001-10-01 Bristol Myers Squibb Co Preparation of 3-fluoro oxindole derivatives
DK1147134T3 (da) * 1999-01-26 2007-02-05 Neurosearch As Hidtil ukendte kaliumkanaler og gener, der koder for disse kaliumkanaler
WO2001010381A2 (en) * 1999-08-04 2001-02-15 Icagen, Inc. Methods for treating or preventing pain and anxiety

Also Published As

Publication number Publication date
AU2001273887B2 (en) 2005-12-15
AU7388701A (en) 2002-01-08
CN1222288C (zh) 2005-10-12
JP2004501192A (ja) 2004-01-15
AU2001273887B9 (en) 2006-02-02
CA2412208C (en) 2009-08-18
EP1634594A1 (de) 2006-03-15
ATE311879T1 (de) 2005-12-15
DE60115656D1 (de) 2006-01-12
MXPA03000032A (es) 2003-08-19
NZ522794A (en) 2005-04-29
DE60115656T2 (de) 2006-06-14
US20030181507A1 (en) 2003-09-25
EP1303269B1 (de) 2005-12-07
CA2412208A1 (en) 2002-01-03
CN1438885A (zh) 2003-08-27
EP1303269A1 (de) 2003-04-23
WO2002000217A1 (en) 2002-01-03

Similar Documents

Publication Publication Date Title
DK1303269T3 (da) 3-substituerede oxindolderivater og deres anvendelse som KCNQ-kaliumkanalmodulatorer
NO20061092L (no) Heteroarvlaminosulfonvlfenvl-derivater for anvendelse som natrium- eller kalslumkanalblokkere i behandlingen av smerte
NO20030374D0 (no) Syklopentanoindoler, preparater som inneholder slike forbindelser og behandlingsfremgangsmåter
NO20032831D0 (no) Pyrimidinaminer som angiogenese-modulatorer
NO20083220L (no) Heterocykliske derivater som modulatorer for ionekanaler
ATE472529T1 (de) Prolinamidderivate als natriumkanalmodulatoren
DE60225040D1 (de) Montelukast-granulatformulierung
NO20061845L (no) Fenyl-piperazinderivater som modulatorer for muskarine reseptorer
NO20074959L (no) Substituerte pyridinderivater
SE0203713D0 (sv) Novel compounds
NO20071438L (no) 4-arylspirosykloalky 1-2-aminopyrimidinkarboksamid KCNQ kaliumkanal modulerende forbindelser
NO20060402L (no) 3-amino choman og 2-aminotetralinderivater
BR0215360A (pt) Derivados de indolina úteis como inibidores de proteìna quinase
NO20033683D0 (no) 2,4-disubstituerte pyrimidin-5-karboksamidderivater som KCNQ kaliumkanal modulatorer
DK1682530T3 (da) Pyrrolsubstituerede indoler som inhibitorer af PAI-1
ATE288747T1 (de) Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren
AU2001273887A1 (en) Use of 3-substituted oxindole derivatives as KCNQ potassium channel modulators
DK1456212T3 (da) 6-aminomorphinanderivater, fremgangsmåder til fremstilling heraf og disses anvendelse
ATE542796T1 (de) N-sulfonylcarboximidamidverbindungen als apoptosepromotoren
NO20043952L (no) Benzofuran- og benzotiofenderivater som er nyttige ved behandling av hyperproliferative forstyrrelser
DK1448562T3 (da) Substituerede tetracycliske pyrroloquinolonderivater egnede som phosphodiesteraseinhibitorer
BRPI0507987A (pt) métodos e compostos moduladores receptor de glicocorticóide
BR0318521A (pt) arilindenopiridinas e arilindenopirimidinas e métodos terapêuticos e profiláticos relacionados
DE60316128D1 (de) N-sulfonylurea-apoptosis-förderer
DE602004018811D1 (de) Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren